Newsroom | 19270 results

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Presents Positive Preclinical Data on ABCL575 at the SID Annual Meeting 2025...

PORTLAND, Maine--(BUSINESS WIRE)--BerryDunn, a full-service accounting, tax, and consulting firm, will host its third annual Healthcare Leadership Summit on May 14, 2025. The virtual half-day event will focus on critical topics of importance to healthcare executives, ranging from staffing shortages and compliance issues to Medicare reimbursement and leveraging AI for efficiencies. As part of BerryDunn’s ongoing commitment to healthcare industry leadership, this year’s Summit brings together a d...

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in three upcoming investor conferences. Wednesday, May 14, 2025, at 5:00 p.m. (PT) – Fireside chat at the 2025 Bank of America Securities Healthcare Conference in Las Vegas Wednesday, June 4, 2025, at 1:20 p.m. (CT) – Presentat...

NEW YORK--(BUSINESS WIRE)--QuantHealth, an AI-powered clinical trial simulation company, today unveiled its Large Real-World Drug Model (LRDM v1.0), a first-of-its-kind clinical trial foundation model that can process and utilize data from more than 100 million patients and billions of therapeutic datapoints in a single simulation. Leveraging end-to-end transformer architectures, QuantHealth’s LRDM v1.0 represents a fundamental breakthrough in using AI to predict drug effectiveness and patient...

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its first quarter results for 2025 via pre-recorded conference call and webcast on Thursday, May 15, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID: 13753498 Webcast Li...

CAMBRIDGE, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Lightcast announced the limited commercial release of its Envisia™ platform — a breakthrough droplet-based, single-cell functional analysis system....

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2025 financial results and highlighted recent corporate updates. “We have made significant progress in planning for our future registrational trial with NGN-401 gene therapy for Rett syndrome and expect to provide an update on our plans during the first half of this year,...

SAN DIEGO & TOKYO & MALVERN, Pa.--(BUSINESS WIRE)--Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a prospective sample acquisition as part of the strategic partnership to advance the development of biomarkers for Alzheimer’s disease and other neurodegenerative conditions. This milestone marks the fulfillment of AriBio’s commitment to provide plasma and matched cerebral spinal fluid samples from the ongoing Phase...

MENLO PARK, California--(BUSINESS WIRE)--Elegen, líder en la fabricación de ADN sin células de última generación, anunció hoy el lanzamiento de acceso anticipado ENFINIA™ IVT Ready DNA. Este nuevo producto es una ampliación de su plataforma ENFINIA; se entrega listo para usar con la cola de poli(A) necesaria ya codificada. Su disponibilidad comercial está prevista a escala mundial para principios del verano de 2025. Basado en la tecnología sin células patentada de Elegen, ENFINIA IVT Ready DNA,...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced of...